Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 12.71 Million USD | -19.78% |
| 2021 | 15.84 Million USD | 0.0% |
| 2019 | 22.57 Million USD | -41.72% |
| 2018 | 38.74 Million USD | -7.44% |
| 2017 | 41.85 Million USD | 22.59% |
| 2016 | 34.14 Million USD | 70.66% |
| 2015 | 20 Million USD | 136.55% |
| 2014 | 8.45 Million USD | 160.26% |
| 2013 | -14.03 Million USD | 59.47% |
| 2012 | -34.63 Million USD | -40.64% |
| 2011 | -24.62 Million USD | -215.71% |
| 2010 | 21.28 Million USD | -18.98% |
| 2009 | 26.27 Million USD | 56.95% |
| 2008 | 16.73 Million USD | -32.55% |
| 2007 | 24.81 Million USD | 55.05% |
| 2006 | 16 Million USD | 142.68% |
| 2005 | 6.59 Million USD | 116.52% |
| 2004 | 3.04 Million USD | 116.34% |
| 2003 | 1.4 Million USD | 174.54% |
| 2002 | 512.82 Thousand USD | 173.81% |
| 2001 | 187.29 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 1.1 Million USD | -23.7% |
| 2023 Q2 | 1.44 Million USD | 0.0% |
| 2022 Q4 | 2.51 Million USD | 13.79% |
| 2022 Q2 | 2.03 Million USD | -65.75% |
| 2022 FY | 12.71 Million USD | -19.78% |
| 2022 Q3 | 2.21 Million USD | 8.54% |
| 2022 Q1 | 5.94 Million USD | 6.75% |
| 2021 Q4 | 5.57 Million USD | 6.56% |
| 2021 Q1 | 1.64 Million USD | 0.0% |
| 2021 FY | 15.84 Million USD | 0.0% |
| 2021 Q2 | 3.4 Million USD | 106.93% |
| 2021 Q3 | 5.22 Million USD | 53.7% |
| 2020 Q3 | 3.35 Million USD | -19.06% |
| 2020 Q1 | 1.62 Million USD | -57.96% |
| 2020 Q2 | 4.14 Million USD | 155.8% |
| 2019 FY | 22.57 Million USD | -41.72% |
| 2019 Q4 | 3.85 Million USD | -50.28% |
| 2019 Q3 | 7.75 Million USD | -16.91% |
| 2019 Q2 | 9.33 Million USD | -13.61% |
| 2019 Q1 | 10.8 Million USD | 15.44% |
| 2018 Q3 | 10.9 Million USD | 42.4% |
| 2018 Q1 | 10.47 Million USD | -18.78% |
| 2018 Q2 | 7.66 Million USD | -26.85% |
| 2018 Q4 | 9.36 Million USD | -14.16% |
| 2018 FY | 38.74 Million USD | -7.44% |
| 2017 Q3 | 9.58 Million USD | 7.54% |
| 2017 FY | 41.85 Million USD | 22.59% |
| 2017 Q4 | 12.89 Million USD | 34.58% |
| 2017 Q1 | 9.76 Million USD | 1.12% |
| 2017 Q2 | 8.9 Million USD | -8.8% |
| 2016 FY | 34.14 Million USD | 70.66% |
| 2016 Q1 | 7.62 Million USD | 60.5% |
| 2016 Q3 | 7.59 Million USD | 6.82% |
| 2016 Q4 | 9.66 Million USD | 27.14% |
| 2016 Q2 | 7.11 Million USD | -6.66% |
| 2015 Q4 | 4.74 Million USD | 14.63% |
| 2015 Q3 | 4.14 Million USD | 18.57% |
| 2015 Q1 | -13.95 Million USD | -824.45% |
| 2015 Q2 | 3.49 Million USD | 125.04% |
| 2015 FY | 20 Million USD | 136.55% |
| 2014 FY | 8.45 Million USD | 160.26% |
| 2014 Q4 | 1.92 Million USD | 6.76% |
| 2014 Q3 | 1.8 Million USD | 2.15% |
| 2014 Q2 | 1.76 Million USD | 160.38% |
| 2014 Q1 | -2.92 Million USD | -256.75% |
| 2013 Q4 | 1.86 Million USD | -14.21% |
| 2013 Q1 | -9.4 Million USD | -12.7% |
| 2013 Q2 | -7.07 Million USD | 24.83% |
| 2013 Q3 | 2.17 Million USD | 130.76% |
| 2013 FY | -14.03 Million USD | 59.47% |
| 2012 Q1 | 6.87 Million USD | 225.37% |
| 2012 Q2 | -8.59 Million USD | -225.11% |
| 2012 FY | -34.63 Million USD | -40.64% |
| 2012 Q3 | -8.28 Million USD | 3.62% |
| 2012 Q4 | -8.34 Million USD | -0.69% |
| 2011 Q4 | -5.48 Million USD | -178.64% |
| 2011 Q1 | 6.75 Million USD | 39.17% |
| 2011 Q2 | 5.3 Million USD | -21.49% |
| 2011 Q3 | 6.97 Million USD | 31.4% |
| 2011 FY | -24.62 Million USD | -215.71% |
| 2010 Q2 | 5.45 Million USD | -2.21% |
| 2010 Q4 | 4.85 Million USD | -4.56% |
| 2010 FY | 21.28 Million USD | -18.98% |
| 2010 Q1 | 5.58 Million USD | 21.57% |
| 2010 Q3 | 5.08 Million USD | -6.78% |
| 2009 Q4 | 4.59 Million USD | 17.26% |
| 2009 FY | 26.27 Million USD | 56.95% |
| 2009 Q3 | 3.91 Million USD | -15.4% |
| 2009 Q2 | 4.62 Million USD | 24.01% |
| 2009 Q1 | 3.73 Million USD | -24.18% |
| 2008 FY | 16.73 Million USD | -32.55% |
| 2008 Q2 | 4.28 Million USD | -32.03% |
| 2008 Q3 | 4.71 Million USD | 10.13% |
| 2008 Q4 | 4.92 Million USD | 4.28% |
| 2008 Q1 | 6.3 Million USD | 14.09% |
| 2007 FY | 24.81 Million USD | 55.05% |
| 2007 Q3 | 7.06 Million USD | 23.49% |
| 2007 Q2 | 5.71 Million USD | -28.28% |
| 2007 Q1 | 7.97 Million USD | 112.18% |
| 2007 Q4 | 5.52 Million USD | -21.75% |
| 2006 Q1 | 2.1 Million USD | 57.0% |
| 2006 FY | 16 Million USD | 142.68% |
| 2006 Q2 | 1.8 Million USD | -14.22% |
| 2006 Q3 | 2.84 Million USD | 57.55% |
| 2006 Q4 | 3.75 Million USD | 31.94% |
| 2005 Q3 | 1.83 Million USD | 56.41% |
| 2005 FY | 6.59 Million USD | 116.52% |
| 2005 Q2 | 1.17 Million USD | 12.7% |
| 2005 Q1 | 1.03 Million USD | 7.35% |
| 2005 Q4 | 1.34 Million USD | -26.69% |
| 2004 Q1 | 720.22 Thousand USD | 203.66% |
| 2004 FY | 3.04 Million USD | 116.34% |
| 2004 Q2 | 450.06 Thousand USD | -37.51% |
| 2004 Q3 | 566.44 Thousand USD | 25.86% |
| 2004 Q4 | 967.72 Thousand USD | 70.84% |
| 2003 Q1 | 248.24 Thousand USD | 161.06% |
| 2003 Q3 | 147.58 Thousand USD | -48.46% |
| 2003 Q4 | 237.17 Thousand USD | 60.7% |
| 2003 Q2 | 286.37 Thousand USD | 15.36% |
| 2003 FY | 1.4 Million USD | 174.54% |
| 2002 Q3 | 13.73 Thousand USD | -48.71% |
| 2002 Q4 | 95.09 Thousand USD | 592.43% |
| 2002 Q2 | 26.77 Thousand USD | 433.16% |
| 2002 Q1 | 5022.13 USD | 0.0% |
| 2002 FY | 512.82 Thousand USD | 173.81% |
| 2001 FY | 187.29 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -851.902% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -152.12% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 56.986% |
| Nascent Biotech, Inc. | 2.22 Million USD | -470.076% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1814.458% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 65.879% |
| Qrons Inc. | 643.67 Thousand USD | -1874.904% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3163.118% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 77.869% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2959.601% |
| Skye Bioscience, Inc. | 13.54 Million USD | 6.168% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 85.352% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -158.484% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -4756.988% |
| SQZ Biotechnologies Company | 85.61 Million USD | 85.153% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -335.905% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -746.395% |
| Mesoblast Limited | 5.9 Million USD | -115.385% |
| Marizyme, Inc. | 19.23 Million USD | 33.929% |
| Genus plc | 147.7 Million USD | 91.393% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -44.796% |
| Pharming Group N.V. | 225.49 Million USD | 94.363% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -520.49% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -847.564% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -52.44% |
| ContraFect Corporation | 56.88 Million USD | 77.655% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -188.341% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -759.644% |
| IMV Inc. | 37.7 Million USD | 66.289% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -355.569% |
| MultiCell Technologies, Inc. | 567.42 USD | -2240215.815% |
| ONE Bio Corp. | 6.44 Million USD | -97.272% |
| Accustem Sciences Inc. | 3.74 Million USD | -239.311% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 85.209% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2289.644% |
| Q BioMed Inc. | 3.43 Million USD | -269.897% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 48.566% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -383.802% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1178.639% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 87.202% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -622.405% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -89.223% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -581.839% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 50948.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 20.601% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -592.716% |
| GB Sciences, Inc. | 1.42 Million USD | -794.89% |
| Alpha Cognition Inc. | 9.7 Million USD | -30.976% |
| HST Global, Inc. | 140.9 Thousand USD | -8921.553% |
| CSL Limited | 3.44 Billion USD | 99.631% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1030.046% |
| Halberd Corporation | 74.84 Thousand USD | -16885.115% |
| Enzolytics Inc. | 2.17 Million USD | -483.251% |
| Agentix Corp. | 1.37 Million USD | -826.695% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -248.207% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.171% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1117.625% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -428.58% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -704.886% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -273.336% |
| AVAX Technologies, Inc. | 7.31 Million USD | -73.892% |
| Zenith Capital Corp. | 8.94 Million USD | -42.145% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.46% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -72869.405% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -417.734% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -7311.856% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -561.771% |
| Kadimastem Ltd | 2.41 Million USD | -427.444% |
| Helix BioMedix, Inc. | 1.97 Million USD | -544.614% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -16.978% |
| BioStem Technologies, Inc. | 22.97 Million USD | 44.67% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -6904.436% |
| LadRx Corporation | 3.81 Million USD | -233.492% |
| Cell Source, Inc. | 4.32 Million USD | -193.896% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1276.488% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1276.488% |
| NovAccess Global Inc. | 2.46 Million USD | -415.332% |
| Affymax, Inc. | 39.38 Million USD | 67.725% |
| Itoco Inc. | 919.14 Thousand USD | -1283.027% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -199.924% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1036.014% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2192.326% |
| CytoDyn Inc. | 18.05 Million USD | 29.605% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -50406.576% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -5676.134% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -795.342% |
| SYBLEU INC | 160.87 Thousand USD | -7801.738% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -599.877% |
| International Stem Cell Corporation | 5.27 Million USD | -141.169% |
| Bioxytran, Inc. | 3.82 Million USD | -232.762% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -24048.019% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -62388.325% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 64.948% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -685.661% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1627.561% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -308.615% |
| Neutra Corp. | 243.82 Thousand USD | -5113.661% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 27.181% |
| PureTech Health plc | 144.59 Million USD | 91.209% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 37.96% |
| IXICO plc | 4.7 Million USD | -170.066% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -44.504% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 89.204% |
| CSL Limited | 3.89 Billion USD | 99.673% |
| Cellectis S.A. | 97.32 Million USD | 86.938% |